Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 13Stomach Neoplasms 3Neoplasm Metastasis 3Carcinoma, Hepatocellular 3Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Unresectable Locally Advanced or Metastatic Solid Tumors 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Osteosarcoma 1Mesothelioma, Malignant 1Melanoma 1Glioblastoma 1Gastrointestinal Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Esophageal Squamous Cell Carcinoma 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Merkel Cell 1Brain Neoplasms 1

Interventions

regorafenib 1napabucasin 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Gastrointestinal Cancer × regorafenib × Clear all
NCT02024607 2023-11-15

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Sumitomo Pharma America, Inc.

Phase 1/2 Completed
495 enrolled 18 charts
Gastrointestinal

Advanced Gastrointestinal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡